Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
126 hedge funds and large institutions have $209M invested in Eagle Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 47 increasing their positions, 50 reducing their positions, and 39 closing their positions.
460% more call options, than puts
Call options by funds: $56K | Put options by funds: $10K
6% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 50
18% less funds holding
Funds holding: 153 → 126 (-27)
37% less capital invested
Capital invested by funds: $334M → $209M (-$125M)
69% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 39
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$7.02M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$5.7M |
| 3 |
LSV Asset Management
Chicago,
Illinois
|
+$3.91M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$2.43M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$20.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7.24M |
| 3 |
DZ Bank
Frankfurt Am Main,
Germany
|
-$4.72M |
| 4 |
State Street
Boston,
Massachusetts
|
-$3.92M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.2M |
EGRX Hedge Fund Activity: Q2 2023 in Review
126 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2023, worth a combined $209M — down 37% from $334M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of EGRX and 12 opened new positions — a net loss of 27 holders — while 50 trimmed existing stakes and 47 added.
The largest buyer was Brandes Investment Partners, adding an estimated $7.02M. The largest seller was BlackRock, cutting an estimated $20.5M.
- 126 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2023, down from 153 in Q1 2023.
- Funds reported $209M of Eagle Pharmaceuticals, Inc. stock for Q2 2023, down 37% quarter-over-quarter.
- 12 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2023 and 39 closed out, a net change of -27 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2023 was Brandes Investment Partners, an estimated $7.02M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2023 was BlackRock, an estimated $20.5M sold.
Based on aggregated 13F filings for Q2 2023.